(13d) Phenyl (ethoxy-L-alaninyl)phosphorochloridate
The title compound was synthesised according to the general procedure B using phenyl phosphorodichloridate (0.53 ml, 3.58 mmol), L-alanine ethyl ester hydrochloride (500 mg, 3.25 mmol), TEA (0.95 ml, 6.82 mmol) and DCM (10 ml). Yellowish/orange grease, 1.14 g, (~quant.) 
(13e) Phenyl (methoxy-L-valinyl)phosphorochloridate
The title compound was synthesised according to the general procedure B from L-valine methyl ester hydrochloride (500 mg, 2.98 mmol), phenyl phosphorochloridate (0.49 ml, 3.28 mmol), TEA (0.87 ml, 6.26 mmol) and DCM (12 ml). Colourless oil, 1.29 g, (~quant.).
1 HNMR (500 MHz, CDCl 3 ) δ: 0.87 (dd, 3H, J 1 =6.7 Hz, J 2 =6.9 Hz, 1 of CH(CH 3 ) 2 ); 0.95 (dd, 3H, J 1 =6.8 Hz, J 2 =12.8 Hz, 1 of CH(CH 3 ) 2 ); 2.05-2.13 (m, 1H, CH(CH 3 ) 2 ); 3.71 (d, 3H, 7 .81 Hz, OCH 3 ); 3. 1H, NHCHCH(CH 3 ) 2 ); 4. 1H, NH); 5H, ArH) .
13 CNMR (125 MHz, CDCl 3 ) δ: 17. 29, 17.36, 18.90, 19.01 (CH(CH 3 ) 2 ); 32. 06, 32.12, 32.14, 32.19 (CH(CH 3 ) 2 ); 52.49, 52.53 (OCH 3 ); 59. 79, 60.50 (NHCH); 120.49, 120.53, 120.54, 120.58, 120.62 (ArCH); 126.02, 127.18 (ArCH); 129.62, 129.94, 130.30, 130.32 (ArCH); 149.73, 172.10, 172.13, 172.42 
(13f) Phenyl (ethoxy-L-vanilyl)phosphorochloridate
The title compound was synthesised according to the general procedure B phenyl phosphorodichloridate (491 μl, 3.30 mmol), L-valine ethyl ester hydrochloride (500 mg, 2.75 mmol), TEA (803 μl, 5.77 mmol) and DCM (10 ml). 
(13g) Phenyl (tert-butoxy-L-valinyl)phosphorochloridate
The title compound was synthesised according to the general procedure B from phenyl phosphorodichloridate (232 μl, 1.56 mmol), L-valine tert-butyl ester hydrochloride (273 mg, 1.3 mmol), TEA (380 μl, 2.73 mmol) and DCM (5 ml). Colourless oil, 633 mg (~quant.) 31 PNMR (121 MHz, CDCl 3 ) δ: 9.69, 9.27.
(13h) (4-methyl)phenyl (methoxy-L-alaninyl)phosphorochloridate
The title compounds was prepared according to the general procedure B from (4-methyl)phenyl phoshporodichloridate 12c (900 mg, 4 mmol), Ala-OMe hydrochloride (280 mg, 2 mmol), TEA (700 μl, 5 mmol) and DCM (15 ml). Yellowish oil; 0.95 g (81%).
31 PNMR (121 MHz, CDCl 3 ) δ: 8.11, 7.72
(13i) (4-methyl)phenyl (ethoxy-L-alaninyl)phosphorochloridate
The title compound was synthesised following the general procedure B, using (4-methyl)phenyl phosphorodichloridate 12c (1 g, 4.44 mmol), L-alanine ethyl ester hydrochloride (569 mg, 3.70 mmol), TEA (1.08 ml, 7.77 mmol) and DCM (15 ml). Colourless oil, 1.35 g (99% 
(13j) (4-methyl)phenyl (ethoxy-L-alaninyl)phosphorochloridate
The title compound was prepared according to the general procedure B starting from (4-methyl)phenyl phosphorodichloridate 12c (805 mg, 3.58 mmol), L-valine methyl ester hydrochloride (500 mg, 2.98 mmol), TEA (0.87 ml, 2.26 mmol) and DCM (10 ml). 
(13l) (4-methyl)phenyl (ethoxy-L-valinyl)phosphorochloridate (AKA GFRII-48)
The title compound was synthesised according to the general procedure B, using toluyl phosphorodichloridate 12c (770 mg, 3.42 mmol), L-valine ethyl ester hydrochloride (500 mg, 2.75 mmol), TEA (803 μl, 5.77 mmol) and DCM (10 ml). Colourless oil, 1.03 g (93%).
31
PNMR (121 MHz, CDCl 3 ) δ: 9.63, 9.16.
(13m) (4-methoxy)phenyl (methoxy-L-alaninyl)phosphorochloridate
The title compound was synthesised according to the general procedure B from (4-methyl)phenyl phosphorodichloridate 12c (1.04 g, 4.29 mmol), L-alanine methyl ester hydrochloride (500 mg, 3.58 mmol), TEA (1.1 ml, 7.88 mmol) and DCM (15 ml). Yellow oil, 1.43 g (~quant. The title compound was synthesised according to the general procedure C using phenyl-valOEt phosphorochloridate 13d (341 mg, 1.17 mmol), N-2,4-dimethoxybenzyloxy-2,3-O-isopropylideneerythronocarboxamide 10 (200 mg, 0.58 mmol), NMI (186 μl, 2.34 mmol) and DCM (10 ml). Yellowish sticky oil, 212 mg (61% 
(14g) N-2,4-dimethoxybenzyloxy-2,3-O-isopropylidene erythrono carboxamide-4-[phenyl (tert-butoxyvalinyl) phosphoramidate]
The title compound was prepared following the general procedure C using phenyl val-OtBu phosphorochloridate 13g (407 mg, 1.17 mmol), 2,4-dimethoxybenzyl erythronohydroxamate 10 (200 mg, 0.58 mmol), NMI (186 μl, 2.34 mmol) and DCM (10 ml). Colourless sticky oil, 181 mg (47%). 
(14i) N-2,4-dimethoxybenzyloxy-2,3-O-isopropylidene erythrono carboxamide -4-[(4-methyl)phenyl (ethoxyalaninyl) phosphoramidate]
The compound was synthesised following the general procedure C using toluyl-Ala-OEt phosphorochloridate 13i (214 mg, 0.70 mml), N-2,4-dimethoxybenzyloxy-2,3-O-isopropylidene erythronocarboxamide 10 (200 mg, 0.58 mmol), NMI (233 μl, 2.93 mmol) and DCM (10 ml). Colourless sticky oil, 93 mg (26% The title compound was synthesised following the general procedure C using (4-methoxy)phenyl Ala-OMe phosphorochloridate 13m (360 mg, 1.17 mmol), N-2,4-dimethoxybenzyloxy-2,3-Oisopropylidene-erythronocarboxamide 10 (200 mg, 0,58 mmol), NMI (186 μl, 2.34 mmol) and DCM (10 ml). Colourless sticky oil, 103 mg (28% (14n) N-2,4-dimethoxybenzyloxy-2,3-O-isopropylidene erythrono carboxamide-4-[(2,3- 
dimethyl)phenyl (ethyloxyvalinyl)phosphoramidate]
The compound was synthesized according to the general procedure C from the phosphorodichloridate 13n (222 mg, 0.63 mmol), 2,4-dimethoxybenzyl-2,3-O-isopropylidene erythrono hydroxamate 10 (180 mg, 0.53 mmol), NMI (167 μl, 2.11 mmol) in DCM (3 ml). Colorless oil, 40 mg (12% 
(14o) N-2,4-dimethoxybenzyloxy-2,3-O-isopropylidene erythrono carboxamide-4-[(2,3-dimethyl)phenyl (methyloxyalaninyl)phosphoramidate]
The title compound was synthesised following the general procedure C using (2,3-dimethyl)phenyl-(methoxy-alanilyl) phosphorochloridate 13o (362 mg, 1.18 mmol), N-2,4-dimethoxybenzyloxy-2,3-O-isopropylidene-erythronocarboxamide 10 (337 mg, 0.98 mmol), NMI (311 μl, 3.92 mmol) and DCM (6 ml). Colourless oil, 28 mg (~5% 
(14p) N-2,4-dimethoxybenzyloxy-2,3-O-isopropylidene erythrono carboxamide-4-[(2,3-dimethyl)phenyl (ethyloxyvalinyl)phosphoramidate
The title compound was prepared following the general procedure C using (O-2,3-dimethyl)phenyl-(ethoxy-valinyl) 13p phosphorochloridate (460 mg, 1.32 mmol), N-2,4-dimethoxybenzyloxy-2,3-O-isopropylidene-erythronocarboxamide 10 (375 mg, 1.10 mmol), NMI (374 μl, 4.40 mmol) and DCM (7 ml 
(15g) 2,3-O-isopropylidene erythronocarboxamide-4-[phenyl (tertbutoxyvalinyl)phosphoramidate]
The title compound was synthesised following the general procedure D from 14g (181 mg, 0.28 mmol), TFA (50 μl) and DCM (5 ml). White foam, 74 mg (53%). 
